These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3615340)

  • 1. Cefotaxime disposition pharmacokinetics during peritoneal dialysis.
    Overgaard S; Løkkegaard N; Scrøder S; Fugleberg S; Nielsen-Kudsk F
    Pharmacol Toxicol; 1987 May; 60(5):321-4. PubMed ID: 3615340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.
    Albin HC; Demotes-Mainard FM; Bouchet JL; Vincon GA; Martin-Dupont C
    Clin Pharmacol Ther; 1985 Sep; 38(3):285-9. PubMed ID: 4028623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cefotaxime in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis.
    Hasegawa H; Imada A; Horiuchi A; Nishii Y; Fukushima M; Kurokawa E
    J Antimicrob Chemother; 1984 Sep; 14 Suppl B():135-42. PubMed ID: 6094432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis.
    Ti TY; Fortin L; Kreeft JH; East DS; Ogilvie RI; Somerville PJ
    Antimicrob Agents Chemother; 1984 Jan; 25(1):83-7. PubMed ID: 6322683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis.
    Heim KL; Halstenson CE; Comty CM; Affrime MB; Matzke GR
    Antimicrob Agents Chemother; 1986 Jul; 30(1):15-9. PubMed ID: 3752976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cefotaxime in the domestic cat.
    McElroy D; Ravis WR; Clark CH
    Am J Vet Res; 1986 Jan; 47(1):86-8. PubMed ID: 3946912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis.
    Burgess ED; Blair AD
    Antimicrob Agents Chemother; 1983 Aug; 24(2):237-9. PubMed ID: 6314887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis.
    Chodos J; Francke EL; Saltzman M; Neu HC
    Ther Drug Monit; 1981; 3(1):71-4. PubMed ID: 6262952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefotaxime and metabolite disposition in two pediatric continuous ambulatory peritoneal dialysis patients.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JA
    Ann Pharmacother; 1992 Mar; 26(3):341-3. PubMed ID: 1554953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.
    Paton TW; Cornish WR; Manuel MA; Hardy BG
    Clin Pharmacokinet; 1985; 10(5):404-25. PubMed ID: 3899455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cefotaxime in the dog.
    Guerrini VH; English PB; Filippich LJ; Schneider J; Bourne DW
    Vet Rec; 1986 Jul; 119(4):81-3. PubMed ID: 3750783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.
    Ings RM; Reeves DS; White LO; Bax RP; Bywater MJ; Holt HA
    J Pharmacokinet Biopharm; 1985 Apr; 13(2):121-42. PubMed ID: 4057054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of intravenous ceftizoxime in patients on continuous ambulatory peritoneal dialysis.
    Johnson CA; Zimmerman SW; Bayer W; Craig WA
    Clin Nephrol; 1985 Mar; 23(3):120-4. PubMed ID: 3857136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis.
    Petersen J; Stewart RD; Catto GR; Edward N
    Nephron; 1985; 40(1):79-82. PubMed ID: 4000338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.
    Ohkawa M; Okasho A; Motoi I; Tokunaga S; Shoda R; Kawaguchi S; Sawaki M; Shimamura M; Hirano S; Kuroda K; Awazu S
    Chemotherapy; 1983; 29(1):4-12. PubMed ID: 6299656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.
    Merdjan H; Baumelou A; Diquet B; Chick O; Singlas E
    Br J Clin Pharmacol; 1985 Feb; 19(2):211-7. PubMed ID: 3986079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis.
    Sica DA; Polk RE; Kerkering TM; Patterson P; Baggett J
    Eur J Clin Pharmacol; 1986; 30(6):713-7. PubMed ID: 3464435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doses of antibiotic in patients with renal insufficiency.
    Ohkawa M; Kuroda K
    Clin Ther; 1981; 4 Suppl A():124-32. PubMed ID: 6275994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cefotaxime in sheep.
    Guerrini VH; Filippich L; English PB; Bourne DW
    Am J Vet Res; 1983 Aug; 44(8):1488-91. PubMed ID: 6312852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.